How can we help?

You can also find more resources in our Help Center.

Chemotherapy and Leukemias

STUDY
PLAY
acute Lymphocytic Leukemia stages
primarily childhood (ages 1-10)
remission induction (1-2 months;absence of symptoms, absence of hematologic alterations)> CNS prophylasis (1 month; high metastasis to the brain; continue throughout if pediatric)> consolidation (3-9 months; intensification; done to ride body of the cells)> Maintenance (30-36 months)
ALL remission induction drugs
vincristine, prednison, anthracuclin, L-asparaginase with peds
ALL CNS prophylaxis
methotrexate
ALL consolidation
same as remission (maybe cytarabine, 6-MP)
ALL Maintenance
methotrexate and 6-MP, VCR and prednisone
Vincristine
vinca alkaloid, microtubule inhibitor (M phase specific), substrate for MDR pump (increased drug efflux), causes neurotoxicity
Prednison
corticosteroid, suppresses gene expression, Cushin-like effects and psychosis
Anthracycline (-rubicin)
intercalating agent and topoisomerase2 inhibitor (decreases DNA repair), free radicals, MDR substrate, cardiotoxicity (arrythmias; accumulation= CHF)
L-asparaginase
inhibits protein synthesis (makes Asp unavailable to malignant cells)
Methotrexate
folate antimetabolite (some liver and lung fibrosis)
6-MP
purine antimetabolite
Cytarabine
pyrimidine antimetabolite
cyclophoshamide
alkylating agent, hemorrhagic cystitis
AML
disease increases with age (recurrence after age 60)
remission induction> consolidation . HSC ttransplant (if drug tx if not curative) or dictontinue therapy
AML remission induction
cytarabine and daunorubicin (7 and 2 regimen) and an etoposide if pediatric cases
AML consolidation drugs
same as ALL
Acute Promyelocytic Leukemia
ATRA is first choice (in t(15,17): promotes cellular differentiation and reduces proliferation
Arsenic trioxide (increased degradation of product of mutation): promotes differentiation, induces apoptosis
gemtuzumab (CD33 antibody)-ozogamicin (antibody intercalating agent)
CML
in 50s nd 60s
Imatinib (ABL tyrosine kinase inhibitors; not curative)
Interferon- (alpha- antiproliferative agent), plus cytarabine
Hydroxyurea ( inhibits DNA synthesis; ribonucleaotide reductase)
Chronic Lymphocytic Leukemia
disease of the elderly, chronic environmental exposure
Fludaribine or cladribine (purine analog; inhibitor of DNA synthesis) plus cyclophosphamide OR
cyclophosphamide and prednisone (suppresses cellular signaling) often PLUs
Rituximab (mab to CD20; mouse/human) OR
Alemtuzumab (mab to CD 53) or Ofatumumab (CD 20)